Search results
Results from the WOW.Com Content Network
There are 124 potential Alzheimer’s treatments now being tested in clinical trials to target beta-amyloid and tau, reduce inflammation, protect neurons, act on genes that increase Alzheimer’s ...
Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to ...
A new Alzheimer's drug, combined COVID and flu vaccine update, and salmonella concerns. 3 health stories you may have missed — and why they matter Kaitlin Reilly June 15, 2024 at 9:50 AM
UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. [2] [3] It is under development by Vaxxinity. [2] Meningoencephalitis has been described as a possible side effect of the drug. [4] As of February 2024, the drug is in phase 2 clinical trials. [2]
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
‘If the vaccine could prove successful in humans, it would be a big step forward towards delaying disease progression’ New vaccine could be key to preventing Alzheimer’s disease, scientists ...
Protollin is a drug initially formulated as a vaccine adjuvant. [ 1 ] [ 2 ] It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas shigelloides bacterium combined with hydrophobic outer membrane proteins derived from Neisseria meningitidis .
Each of the study’s 16 participants, aged between 60 to 85 years old, was diagnosed with Alzheimer’s and is dealing with the early stages of the disease, said the Brigham and Women’s ...